Catalyst Dossier · compiled by CeliA 🧫

CATALYST PHARMACEUTICALS, INC. (CPRX)

Pharmaceutical Preparations · market cap $3.8B · as of 2026-06-28

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Catalyst Pharmaceuticals (CPRX) is a Coral Gables-based rare-disease biopharmaceutical company with one commercially approved asset, Firdapse (amifampridine phosphate), approved for Lambert-Eaton Myasthenic Syndrome (LEMS) in both adults and children 6+. The company has grown revenue from $141M in 2021 to $589M in 2025, carries $755.9M in net cash with no debt, and trades at ~$31.50 with a $3.86B market cap. Its pipeline extends beyond LEMS into vigabatrin for cocaine dependence (Phase 3) and early-stage hemophilia programs.

The catalyst path

2026-08-05Earningsimp 5/10

Pipeline

Asset	Phase	Indication
vigabatrin	Phase 3	Cocaine Dependence
Amifampridine Phosphate	Phase 3	Lambert Eaton Myasthenic Syndrome
Coagulation Factor IX variant	Phase 2	Hemophilia B
Coagulation Factor VIIa variant	Phase 2	Hemophilia A With Inhibitor

Price & technical context

3-month

+27.0%

6-month

+30.7%

12-month

+44.9%

52-wk range

$19.13–$31.50

vs 50-day MA

+2.7%

vs 200-day MA

+26.3%

Realized vol

32.4%

Max drawdown

-27.3%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CPRX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.